最適治療を極める！　潰瘍性大腸炎　改訂第2版

出版社： 医学と看護社
著者：
発行日： 2020-06-30
分野： 臨床医学：内科  >  胃/腸
ISBN： 9784909888129
電子書籍版： 2020-06-30 （改訂第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,520 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,520 円(税込)

購入する

商品紹介

診断項目の充実を図り、初版後の新しい治療薬を盛り込んだ待望の改訂版！

目次

  • 潰瘍性大腸炎とは
    第１章　UC疾患概念の成立と歴史的背景
    第２章　炎症性腸疾患と遺伝子
    第３章　炎症性腸疾患と生活習慣との関与について
    　１）なぜ、炎症性腸疾患は増加傾向にあるのか？
    　２）原因としての環境因子
    　３）腸内細菌から見たIBDの病態
    第４章　炎症性腸疾患と免疫反応
    第５章　潰瘍性大腸炎の診断
    　１）診断
    　２）潰瘍性大腸炎の診断基準（厚生労働省診断基準）
    　３）潰瘍性大腸炎臨床的重症度診断基準（令和2年改訂）
    　４）厚生労働省研究班の活動期内視鏡所見分類
    　５）Mayo score
    　６）Ulcerative Colitis Endoscopic Index of Severity（UCEIS）
    第６章　潰瘍性大腸炎の治療
    　１．治療の一般方針：治療方針の立て方
    　２．治療法：各論
    　　１）5-aminosalicyclic acid（ASA）製剤
    　　２）ステロイド剤
    　　３）チオプリン製剤
    　　４）白血球除去療法
    　　５）カルシニューリン阻害薬
    　　６）抗TNF-α抗体製剤：インフリキシマブ
    　　７）抗TNF-α抗体製剤：アダリムマブ
    　　８）抗TNF-α抗体製剤：ゴリムマブ
    　　９）ベドリズマブ
    　　10）細胞内シグナルを制御する低分子製剤
    　　11）Ustekinumab

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 UC疾患概念の成立と歴史的背景

P.18 掲載の参考文献
1) Wilks S. Morbid appearances in the intestine of Miss Bankes. Lord Med Gazette. 1859 ; 2 : 264-5.
 
2) 稲田龍吉. 重症潰瘍性大腸炎ニ就テ. 日消誌. 1928 ; 27 : 625-38.
 
3) Weir RF. A new use for the useless appendix in surgical treatment of obstinate colitis. Med Rec. 1902 ; 62 : 201.
 
4) Cario E, Rosenberg IM, Brandwein SL, et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines Toll-like receptors. J Immunol. 2000 ; 164 : 966-72.
PubMed
5) Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001 ; 411 : 603-6.
PubMed

第2章 炎症性腸疾患と遺伝子

P.23 掲載の参考文献
1) Buisine MP, Desreumaux P, Debailleul V, et al. Abnormalities in mucin gene expression in Crohn's disease. Inflamm Bowel Dis. 1999 ; 5 : 24-32.
PubMed
2) Goto Y, Obata T, Kunisawa J, et al. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science. 2014 ; 345 : 1254009.
PubMed
3) Yamazaki K, Umeno J, Takahashi A, et al. A genome-wide association study identifies 2 susceptibility Loci for Crohn's disease in a Japanese population. Gastroenterology. 2013 ; 144 : 781-8.
 
4) Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007 ; 39 : 207-11.
PubMed
5) Salem M, Ammitzboell M, Nys K, et al. ATG16L1 : A multifunctional susceptibility factor in Crohn disease. Autophagy. 2015 ; 11 : 585-94.
PubMed
6) Pei FH, Wang YJ, Gao SL, et al. Vitamin D receptor gene polymorphism and ulcerative colitis susceptibility in Han Chinese. J Dig Dis. 2011 ; 12 : 90-8.
 
7) Sivanesan D, Beauchamp C, Quinou C, et al. IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking. J Biol Chem. 2016 ; 291 : 8673-85.
PubMed
8) Pabst O, Forster R, Lipp M, et al. NKX2.3 is required for MAdCAM-1 expression and homing of lymphocytes in spleen and mucosa-associated lymphoid tissue. EMBO J. 2000 ; 19 : 2015-23.
 
9) Tarlinton D, Light A, Metcalf D, et al. Architectural defects in the spleens of Nkx2-3-deficient mice are intrinsic and associated with defects in both B cell maturation and T cell-dependent immune responses. J Immunol. 2003 ; 170 : 4002-10.
 
10) Lu X, Tang L, Li K, et al. Contribution of NKX2-3 Polymorphisms to Inflammatory Bowel Diseases : A Meta-Analysis of 35358 subjects. Sci Rep. 2014 ; 4 : 3924.
 
11) 仲瀬裕志. IBDの病態. INTESTINE 2018 ; 22 : 225-7.
 

第3章 炎症性腸疾患と生活習慣との関与について

P.32 掲載の参考文献
1) Tobin MV, Logan RF, Langman MJ, et al. Cigarette smoking and inflammatory bowel disease. Gastroenterology. 1987 ; 93 : 316-21.
PubMed
2) Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med. 1994 ; 330 : 811-5.
PubMed
3) Sandborn WJ, Tremaine WJ, Offord KP, et al. Transdermal nicotine for mild to moderately active ulcerative colitis-a randomized, double-blinded, placebo-controlled trial. Ann Intern Med. 1997 ; 126 : 364.
 
4) Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology. 1990 ; 98 : 1123-8.
PubMed
5) Acheson ED, TRUE LOVE SC. Early weaning in the aetiology of ulcerative colitis. A study of feeding in infancy in cases and controls. Br Med J. 1961 ; 2 : 929-33.
PubMed
6) Klement E, Cohen RV, Boxman J, et al. Breastfeeding and risk of inflammatory bowel disease : a systematic review with meta-analysis. Am J Clin Nutr. 2004 ; 80 : 1342-52.
PubMed
7) Xu L, Lochhead P, Ko Y, et al. Systematic review with meta-analysis : breastfeeding and the risk of Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017 ; 46 : 780-9.
PubMed
8) Gilat T, Hacohen D, Lilos P, et al. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol. 1987 ; 22 : 1009-24.
PubMed
9) Andersson RE, Olaison G, Tysk C, et al. Appendectomy and protection against ulcerative colitis. N Eng J Med. 2001 ; 344 : 808-14.
 
10) Vessey M, Jewell D, Smith A, et al. Chronic inflammatory bowel disease, cigarette smoking, and use of oral contraceptives : findings in a large cohort study of women of childbearing age. Br Med J (Clin Res Ed). 1986 ; 292 : 1101-3.
 
11) Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015 ; 37 : 47-55.
PubMed
12) Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011 ; 9 : 88-96.
PubMed
13) Damman CJ, Miller SI, Surawicz CM, et al. The microbiome and inflammatory bowel disease : is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012 ; 107 : 1452-9.
 
14) Ohfuji S, Fukushima W, Watanbe K, et al. Pre-illness isoflavone consumption and disease risk of ulcerative colitis : a multicenter case-control study in Japan. 2014 ; 9 : e110270.
 

第4章 炎症性腸疾患と免疫反応

P.36 掲載の参考文献
1) Arseneau KO, Tamagawa H, Pizarro TT, et al. Innate and adaptive immune responses related to IBD pathogenesis. Curr Gastroenterol Rep. 2007 ; 9 : 508-12.
PubMed
2) Peterson LW, Artis D. Intestinal epithelial cells : Regulators of barrier function and immune homeostasis. Nat Rev Immunol. 2014 ; 14 : 141-53.
PubMed
3) Gabbani T, Deiana S, Annese AL, et al. The genetic burden of inflammatory bowel diseases : Implications for the clinic? Expert Rev Gastroenterol Hepatol. 2016 ; 10 : 1109-17.
PubMed
4) Katsanos KH, Papadakis KA. Inflammatory Bowel Disease : Updates on Molecular Targets for Biologics. Gut liver. 2017 ; 11 : 455-63.
PubMed
5) Sartor RB. Mechanisms of disease : Pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006 ; 3 : 390-407.
PubMed
6) Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2014 ; 118 : 229-41.
 
7) Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology. 2005 ; 129 : 50-65.
PubMed
8) Van Furth R, Cohn ZA, Hirsch JG, et al. The mononuclear phagocyte system : A new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ. 1972 ; 46 : 845-52.
PubMed
9) Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 ; 474 : 298-306.
PubMed
10) 仲瀬裕志. 自然免疫. 獲得免疫の関与. 日本臨床 2018 ; 76 : 83-6.
Medical*Online
11) Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001 ; 15 : 985-95.
PubMed
12) Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med. 2009 ; 206 : 35-41.
PubMed
13) Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011 ; 208 : 1127-33.
PubMed
14) MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005 ; 307 : 1920-5.
PubMed
15) Raphael I, Nalawade S, Eagar TN, et al. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015 ; 74 : 5-17.
PubMed
16) Sakuraba A, Sato T, Kamada N, et al. Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. Gastroenterology. 2009 ; 137 : 1736-45.
PubMed

第5章 潰瘍性大腸炎の診断

P.43 掲載の参考文献
1) 仲瀬裕志. 潰瘍性大腸炎, 消化器病診療第2版, 一般社団法人日本消化器病学会監修,「消化器病診療 (第2版) 」編集委員会編, 医学書院, 2014 ; 104-9.
 
2) 厚生労働省科学研究費補助金 難治性疾患等制作研究事業「難治性炎症腸管障害に関する調査研究」 (鈴木班) 平成30年度 改訂版.
 
3) Trulove SC, Witts LJ. Cortisone in ulcerative colitis ; final report on a therapeutic trial. Br Med J. 1955 ; 2 : 1041-8.
 
4) Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalcylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987 ; 317 : 1625-9.
 
5) Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis : the Ulcerative Colitis Endoscopic Index of Severity [UCEIS]. Gut. 2012 ; 61 : 535-42.
PubMed
6) Travis SP, Schnell D, Feagan BG, et al. The Impact of Clinical Information on the Assessment of Endoscopic Activity : Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 ; 9 : 607-16.
PubMed
7) Ikeya K, Hanai H, Sugimoto K, et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016 ; 10 : 286-95.
 
8) Arai M, Naganuma M, Sugimoto S, et al. The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission. J Crohns Colitis. 2016 ; 10 : 1303-9.
 
9) Vuitton L, Peyrin-Biroulet L, Colombel JF, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials : an international consensus. Aliment Pharmacol Ther. 2017 ; 45 : 801-13.
PubMed

第6章 潰瘍性大腸炎の治療

P.49 掲載の参考文献
1) Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 ; 2 : 892-5.
PubMed
2) van Hees PA, Bakker JH, van Tongeren JH. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis : a study to determine the active therapeutic moiety of sulphasalazine. Gut. 1980 ; 21 : 632-5.
 
3) Klotz U, Maier K, Fischer C, et al. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 ; 303 : 1499-502.
PubMed
4) Campieri M, Lanfranchi GA, Bazzocchi G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981 ; 2 : 270-1.
PubMed
5) Bohm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol. 2014 ; 7 : 369-83.
PubMed
6) Matsuoka K, Kobayashi T, Ueno F, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease.J Gastroenterol. 2018 ; 53 : 305-53.
PubMed
7) Oh-Oka K, Kojima Y, Uchida K, et al. Induction of colonic regulatory T cells by mesalamine by activating the aryl Hydrocarbon receptor. Cell Mol Gasteroenterol Hepatol. 2017 ; 11 : 135-51.
 
8) Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicyclic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis : comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis. 2001 ; 7 : 221-5.
 
9) Kane S, Huo D, Aikend J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003 ; 114 : 39-43.
PubMed
10) Flourie B, Hagege H, Tucat G, et al. Randomised clinical trial : once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis. Aliment Pharmacol Ther. 2013 ; 37 : 767-75.
PubMed
11) Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009 ; 7 : 762-9.
PubMed
12) 鈴木康夫. 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」平成29年度 潰瘍性大腸炎, クローン病治療指針.
 
P.53 掲載の参考文献
1) 日本消化器病学会編. 潰瘍性大腸炎の治療, 炎症性腸疾患 (IBD) ガイドライン 2016 : 48-66.
 
2) Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis : a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007 ; 5 : 103-10.
 
3) Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2 : current management. J Crohns Colitis. 2012 ; 6 : 991-1030.
PubMed
4) Naganuma M, Aoyama N, Suzuki Y, et al. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.J Crohns Colitis. 2016 ; 10 : 828-36.
PubMed
5) Naganuma M, Aoyama N, Tada T, et al. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-tomoderate ulcerative colitis with distal active inflammation : double-blind, randomized study. J Gastroenterol. 2017 Aug 4. doi : 10.1007/s00535-017-1376-4. [Epub ahead of print]
 
P.59 掲載の参考文献
1) Zetterstrom R. G.B. Elion (1918-1999) and G. H. Hitchings (1905-1998) : breakthrough in the treatment of childhood leukaemia. Acta Paediatr. 2006 ; 95 : 898-900.
 
2) Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways : analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann NY Acad Sci. 2006 ; 1072 : 98-113.
PubMed
3) Roblin X, Oussalah A, Chevaux JB, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice : a worldwide survey of experts. Inflamm Bowel Dis. 2011 ; 17 : 2480-7.
PubMed
4) Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterology. 2010 ; 45 ; 1014-21.
 
5) Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014 ; 46 ; 1017-20.
 
6) Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015 ; 33 : 1235-42.
PubMed
7) Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016 ; 16 : 280-5.
PubMed
8) Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 ; 49 : 656-64.
 
9) Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005 ; 22 : 605-11.
PubMed
10) Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013 ; 86 : 539-47.
PubMed
11) Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 ; 22 : 441-6.
 
12) Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996 ; 347 : 215-9.
 
13) Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004 ; 99 : 462-5.
PubMed
14) Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study. Lancet. 2009 ; 374 : 1617-25.
PubMed
15) Fukata N, Okazaki K, Omiya M, et al. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol. 2014 ; 49 : 1299-306.
PubMed
P.61 掲載の参考文献
1) Hanai H, Iida T, Takeuchi K, et al. Adsorptive depletion of elevated proinflammatory CD14+ CD16+ DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008 ; 103 : 1210-6.
PubMed
2) Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009 ; 104 : 2990-5.
PubMed
3) Yoshino T, Nakase H, Minami N, et al. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis : a meta-analysis. Dig Liver Dis. 2014 ; 46 : 219-26.
PubMed
4) Zhu M, Xu X, Nie F, et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis : a meta-analysis. Int J Colorectal Dis. 2011 ; 26 : 999-1007.
PubMed
P.67 掲載の参考文献
1) Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994 ; 330 : 1841-5.
PubMed
2) Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease : immunomodulation by tacrolimus (FK506). Am J Gastroenterol. 1986 ; 93 : 1860-6.
 
3) Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell. 1991 ; 66 : 807-15.
PubMed
4) Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med. 2000 ; 2 : 1-23.
PubMed
5) Kogina K, Shoda H, Yamaguchi Y, et al. Tacrolimus differentially regulates the proliferation of conventional and regulatory CD4 (+) T cells. Mol Cell 2009 ; 28 : 125-30.
PubMed
6) Yoshino T, Nakase H, Honzawa Y, et al. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis. 2010 ; 16 : 2022-33.
PubMed
7) Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis : a five-year experience. Am J Gastroenterol. 1999 ; 94 : 1587-92.
PubMed
8) Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis. 1999 ; 5 : 1-10.
PubMed
9) Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006 ; 4 : 760-5.
PubMed
10) Kobayashi T, Naganuma M, Okamoto S, et al. Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol. 2010 ; 45 : 1129-37.
PubMed
11) Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006 ; 55 : 1255-62.
 
12) Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther. 2008 ; 28 : 589-97.
PubMed
13) Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012 ; 18 : 803-8.
PubMed
14) Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroidrefractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Ther. 2013 ; 37 : 129-36.
PubMed
15) Miyoshi J, Matsuoka K, Inoue N, et al. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis. 2013 ; 7 : e609-14.
PubMed
16) 鈴木康夫. 平成27年度改訂版 潰瘍性大腸炎・クローン病 診断基準・治療指針. 難治性炎症性腸管障害に関する調査研究. 2016 : 1-32.
 
17) Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids : a parallel, open-label randomised controlled trial. Lancet. 2012 ; 380 : 1909-15.
PubMed
18) Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018 ; 67 : 237-43.
PubMed
19) Komaki Y, Komaki F, Micic D, et al. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis : a network meta-analysis. J Gastroenterol Hepatol. 2016 ; 32 : 1143-51.
 
20) Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003 ; 125 : 1025-31.
PubMed
P.74 掲載の参考文献
1) 医薬品インタビューフォーム レミケード(R) 点滴静注用 100, 2017年5月改訂 (第26版)
 
2) Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 ; 353 : 2462-76.
PubMed
3) Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis : a systematic review and network meta-analysis. Ann Intern Med. 2014 ; 160 : 704-11.
PubMed
4) Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids : a parallel, open-label randomised controlled trial. Lancet. 2012 ; 380 : 1909-15.
PubMed
5) Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011 ; 141 : 1194-201.
PubMed
6) Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab : a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010 ; 59 : 49-50.
PubMed
7) Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003 ; 348 : 601-8.
 
8) Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors : Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015 ; 29 : 241-58.
PubMed
9) Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014 ; 146 : 392-400.
PubMed
10) Steenholdt C, Molazahi A, Ainsworth MA, et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission : an observational Danish single center study. Scand J Gastroenterol. 2012 ; 47 : 518-27.
PubMed
11) Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005 ; 72 : 250-6.
PubMed
12) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008 ; 67 : 189-94.
PubMed
13) Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy : expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011 ; 23 : 1150-6.
 
P.78 掲載の参考文献
1) Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial. Gut. 2011 ; 60 : 780-87.
PubMed
2) Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 ; 142 : 257-65.
PubMed
3) Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014 ; 49 : 283-94.
PubMed
4) Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis : Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 ; 109 : 1771-80.
 
5) Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy : results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015 ; 74 : 1087-93.
PubMed
6) 関節リウマチ (RA) に対するTNF 阻害薬使用ガイドライン (2017年3月21日改訂版).
 
7) Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013 ; 62 : 1523-28.
PubMed
P.80 掲載の参考文献
1) 藤井秀二, 村上善紀, 原田寧. ゴリムマブの薬理学的特徴および臨床試験成績. 日薬理誌. 2013 ; 141 : 275-85.
 
2) Hibi T, Imai Y, Senoo A, et al. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis : a phase 3, double-blind, randomized, placebo-controlled study- (PURSUIT-J study). J Gastroenterol. 2017 ; 52 : 1101-11.
PubMed
3) 仲瀬裕志. 薬の知識 ゴリムマブ (シンポニー(R)). 臨床消化器内科. 2018 ; 33 : 677-9.
 
P.83 掲載の参考文献
1) Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004 ; 21 : 527-38.
 
2) Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 ; 369 : 699-710.
PubMed
3) 武田薬品工業株式会社 ホームページ (https://www.takeda.co.jp/news/2017/20170822_7816.html)
 
P.86 掲載の参考文献
1) Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment : a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest liver Physiol. 2016 ; 310 : G155-G162.
PubMed
2) Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 ; 376 : 1723-36.
PubMed
P.91 掲載の参考文献
1) Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 ; 375 : 1946-60.
PubMed
2) Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 ; 48 ; 65-77.
PubMed
3) Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019 ; 381 : 1201-14.
PubMed
4) Ochsenkuhn T, Tillack C, Szokodi D, et al. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J. 2020 ; 8 : 91-8.
PubMed
5) Ollech JE, Rubin DT, Glick L, et al. Ustekinumab Is Effective for the Treatment of Chronic Antibiotic- Refractory Pouchitis. Dig Dis Sci. 2019 ; 64 : 3596-601.
PubMed
6) Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis : first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 ; 48 : 394-409.
PubMed

書評

最近チェックした商品履歴

Loading...